Cargando…

Cysteine mutations impair the structural stability of phosphomannomutase 2 (PMM2) in glycosylation-associated metabolic disorders

Detalles Bibliográficos
Autores principales:	Pan, Yunfan, Lin, Li, Yu, Fan, Sun, Jingmiao, Bai, Guannan, He, Xinyu, Mao, Jianhua, Hu, Lidan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363581/ https://www.ncbi.nlm.nih.gov/pubmed/37492729 http://dx.doi.org/10.1016/j.gendis.2022.10.002

Ejemplares similares

Cysteine Pathogenic Variants of PMM2 Are Sensitive to Environmental Stress with Loss of Structural Stability
por: Yu, Fan, et al.
Publicado: (2023)

Anesthetic management of a child with phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG)
por: Sakai, Wataru, et al.
Publicado: (2017)

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
por: Serrano, Mercedes, et al.
Publicado: (2015)

Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)
por: Taday, Roman, et al.
Publicado: (2020)

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals
por: Pascoal, C., et al.
Publicado: (2022)

Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

Molecular analysis of phosphomannomutase (PMM) genes reveals a unique PMM duplication event in diverse Triticeae species and the main PMM isozymes in bread wheat tissues
por: Yu, Chunmei, et al.
Publicado: (2010)

A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG)
por: Serrano, Natalia Lourdes, et al.
Publicado: (2017)

Correction: Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG)
por: García-López, Roberto, et al.
Publicado: (2016)

Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG)
por: Thiesler, Christina T., et al.
Publicado: (2016)

Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy
por: Izquierdo-Serra, Mercè, et al.
Publicado: (2018)

Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation
por: Lao, Jessica P., et al.
Publicado: (2018)

Ophthalmological and electrophysiological findings in monozygotic twin sisters with phosphomannomutase 2 deficiency (PMM2-CDG) over a period of 37 years
por: Van Hees, Ines, et al.
Publicado: (2019)

A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
por: Citro, Valentina, et al.
Publicado: (2017)

Conformational Response to Ligand Binding in Phosphomannomutase2: INSIGHTS INTO INBORN GLYCOSYLATION DISORDER
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Phosphomannomutase 2 (PMM2) variants leading to hyperinsulinism-polycystic kidney disease are associated with early-onset inflammatory bowel disease and gastric antral foveolar hyperplasia
por: Kiparissi, Fevronia, et al.
Publicado: (2023)

Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.
por: Sharma, Vandana, et al.
Publicado: (2011)

Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model
por: Parkinson, William M., et al.
Publicado: (2016)

Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation
por: Andreotti, Giuseppina, et al.
Publicado: (2013)

Evaluation of Cell Models to Study Monocyte Functions in PMM2 Congenital Disorders of Glycosylation
por: de Haas, Paola, et al.
Publicado: (2022)

PMM no. 1/2
Publicado: (1981)

PMM 83-2
Publicado: (1983)

PMM 7-2
Publicado: (1982)

A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2
por: Chan, Barden, et al.
Publicado: (2016)

Interplay of Impaired Cellular Bioenergetics and Autophagy in PMM2-CDG
por: Ligezka, Anna N., et al.
Publicado: (2023)

Hyperinsulinism May Be Underreported in Hypoglycemic Patients with Phosphomannomutase 2 Deficiency
por: Vurallı, Doğuş, et al.
Publicado: (2022)

PMm2 ASIC: PARISROC
por: MArtin-Chassard, G, et al.
Publicado: (2008)

Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
por: Pettinato, Fabio, et al.
Publicado: (2021)

PMM 24/1 & 2/2
Publicado: (1981)

Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Phosphomannomutase 2 hyperinsulinemia: Recent advances of genetic pathogenesis, diagnosis, and management
por: Chen, Congli, et al.
Publicado: (2023)

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019)

PMM 25/1 & 3/2
Publicado: (1981)

PMM no. 26.1 & 4.2
Publicado: (1981)

PMM no. 27.1 & 5.2
Publicado: (1981)

Mannose supplementation in PMM2-CDG
por: Taday, Roman, et al.
Publicado: (2021)

PMM no. 9
Publicado: (1980)

PMM no. 20
Publicado: (1980)

PMM no. 22
Publicado: (1981)

PMM no. 21
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_vnmspglvbjo3agbnus75fbqge0